{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6"}]}],"title":"acute phase(days 1 through 5)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3"}]}],"title":"delayed phase (days 6 through 8)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1"}]}],"title":"overall"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"complete response (CR) of both acute (days 1 through 5) and delayed (days 6 through 8) CINV, defined by no emetic episodes or use of rescue medications","groups":[{"description":"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.\n\n* Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).\n\nAcute emesis prophylaxis:\n\n* Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.\n* Dexamethasone 20mg PO (orally) daily, D1 and 2\n* Fosaprepitant 150mg IV on day 3\n\nDelayed emesis prophylaxis:\n\n* Fosaprepitant 150mg IV on D5\n* Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8 PRN antiemetics allowed at the discretion of the treating investigator\n* No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods Fosaprepitant: Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophyl","id":"OG000","title":"Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Days 1-8 of chemotherapy regimen","title":"Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting","type":"PRIMARY","unitOfMeasure":"percentage of participants"}